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HIV’s ability to establish latent reservoirs of reactivation-competent virus is the major 
barrier to cure. “Shock and kill” methods consisting of latency-reversing agents (LRAs) 
followed by elimination of reactivating cells through cytopathic effects are under active 
development. However, the clinical efficacy of LRAs remains to be established. Moreover, 
recent studies indicate that reservoirs may not be reduced efficiently by either viral cyto-
pathic or CD8+ T-cell-mediated mechanisms. In this perspective, we highlight challenges 
to T-cell-mediated elimination of HIV reservoirs, including characteristics of responding 
T cells, aspects of the cellular reservoirs, and properties of the latent virus itself. We 
also discuss potential strategies to overcome these challenges by targeting the antiviral 
activity of T cells toward appropriate viral antigens following latency.
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introduction
Combination antiretroviral therapy (cART) durably suppresses HIV, but the virus’ ability to persist 
in a quiescent state within cellular reservoirs prevents its eradication from the body. cART must 
therefore be maintained for life. The “Berlin patient” was cured of HIV following a stem cell trans-
plant from a CCR5Δ32 homozygous donor that repopulated his immune system with virus-resistant 
cells (1), indicating that eradication is possible. But, safer and scalable strategies are clearly needed.
Latent HIV-infected cells produce very low levels of viral RNA and proteins and thus remain 
largely hidden from cellular immunity. Reactivation induces viral protein expression and virion 
production, which should make cells susceptible to viral cytopathic effects and immune targeting. 
However, low basal reactivation rates, maintenance of latent HIV-infected cells through homeostatic 
proliferation (2–6), and survival of cells following reactivation (7) ensure that reservoirs persist after 
many years on cART (8, 9). “Shock-and-kill” methods to reactivate latent cells (“shock”) so they can 
be eliminated through host or viral cytopathic effects (“kill”) (10) have been proposed to achieve 
clinical HIV remission (“functional cure”) or reservoir elimination (“sterilizing cure”). To avoid 
viral spread and establishment of new reservoirs, “shock-and-kill” is conducted in the presence of 
cART – but clinical successes have been limited. While identification of latency-reversing agents 
(LRA) supports the feasibility of this approach, elimination of reactivated cells poses a major barrier 
Abbreviations: CAR, chimeric antigen receptor; cART, combination antiretroviral therapy; CTL, cytotoxic T lymphocyte; 
HDACi, histone deacetylase inhibitor; LRA, latency-reversing agent; SAHA, suberoylanilide hydroxamic acid; TCR, T-cell 
receptor.
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(11, 12). Here, we highlight challenges in this area, including 
limited clinical performance of LRAs, resistance of reservoirs to 
host and viral cytopathic effects, dysfunction of cytotoxic T lym-
phocytes (CTL), and viral immune evasion mechanisms. We also 
discuss strategies to enhance T-cell activity and develop T-cell-
based therapeutics. For a review of antibody-mediated strategies 
for HIV eradication, please see Lee et al. in this series (13).
Limitations of Latency-reversing Agents
Latently infected cells can be induced to express HIV RNA and 
proteins using non-specific activating agents, such as phytohe-
magglutinin or anti-CD3/CD28 antibodies in the case of CD4+ 
T cells, but toxicity from cellular proliferation and inflammatory 
cytokines precludes their use in  vivo. Instead, multiple classes 
of LRAs, including histone deacetylase inhibitors (HDACi), 
bromodomain inhibitors, protein kinase C agonists, cytokines 
such as IL-2 and IL-15, and others, have been identified that 
induce latent cells to produce viral RNA, proteins, and virions 
without causing global T-cell activation [for reviews, see Ref. (14, 
15)]. However, challenges remain. Due to the rarity of latent cells 
in vivo [approximately 1 per 106 resting CD4+ T cells (16, 17)], 
LRA discovery generally relies on cell lines that may not reflect 
reservoir complexity (18). Indeed, while the major HIV reservoir 
is resting CD4+ T cells (19), HIV persists in other cell types, 
tissues, and anatomical compartments (20) that remain largely 
untested using LRAs. Moreover, since latency is maintained via 
numerous mechanisms, including regulation of heterochromatic 
structure (21) and host factors required for gene transcription 
(22), LRAs with distinct mechanisms of action may need to be 
combined to maximize reactivation frequency or magnitude (23). 
Combination approaches may also benefit from reduced toxicity 
due to lower doses of individual agents. Toward this goal, some 
LRAs show synergistic ability to reactivate HIV in vitro (24, 25).
In vivo disruption of HIV latency using LRAs has been difficult 
to achieve. Administration of gamma-chain cytokine IL-7 gener-
ated “blips” of viremia in cART-treated individuals (26); however, 
this may result from productively infected cells rather than from 
reservoir reactivation (27, 28). More recently, three HDACi have 
exhibited limited ability to disrupt latency in  vivo. Specifically, 
elevated levels of intracellular unspliced gag RNA  –  but not 
protein – were observed following administration of vorinostat 
(suberoylanilide hydroxamic acid, SAHA) (29), while panobi-
nostat (30) and romidepsin (31) produced transient low-level 
increases in plasma viremia. While supporting the “shock” 
strategy, none of these agents appreciably reduced reservoir size. 
Moreover, cells became refractory to HDACi treatment following 
serial dosing in vivo (32, 33). Efforts to identify LRAs (or combi-
nations) with greater in vivo potency without significant toxicity 
thus remain paramount.
challenges for t-cell-Mediated Killing of 
Hiv reservoirs
Cytotoxic T lymphocytes play a crucial role in containing HIV 
(34–36). Determinants of CTL-mediated reservoir elimination 
under cART, however, may be distinct from those involved in 
viremia control during untreated infection. For example, whereas 
targeting of conserved viral epitopes – where escape is impossible 
or confers a substantial fitness cost (37–41) – may be desirable for 
natural or vaccine-induced HIV control by CTL (42, 43), this may 
not be critical in the context of latency reactivation since immune 
escape mutations will not emerge under cART. In addition, while 
rapid CTL-mediated killing of infected cells (i.e., before progeny is 
produced) might be optimal during untreated infection (44–46), 
prevention of viral spread by cART may allow effective targeting of 
viral epitopes with slower presentation kinetics. Furthermore, in 
untreated infection, a combination of cytolytic and non-cytolytic 
(e.g., interferon gamma, MIP-1, or RANTES) mechanisms (47) 
contain HIV, but only cytolytic activity is likely to contribute to 
reservoir reduction. Thus, while high-avidity CTL are beneficial 
for natural control of infection (48–50), they may be even more 
crucial to eliminate reservoirs, particularly if LRAs induce only 
low viral antigen levels. But some lessons from natural infec-
tion remain relevant. For example, HIV elite controllers (rare 
individuals who spontaneously suppress HIV plasma viremia to 
<50 RNA copies/mL in the absence of cART) harbor significantly 
lower proviral DNA levels, underscoring their potential utility to 
inform research toward a functional cure (51).
resistance of reservoirs to cytopathic effects
Consistent with their longevity in vivo, latently infected resting 
CD4+ T cells resist host and viral cytopathic effects following reac-
tivation. Ex vivo treatment of cells with SAHA had no discernable 
effect on replication-competent HIV load (7), highlighting the 
limited ability of HDACis alone to eliminate HIV (52). Inherent 
features of resting CD4+ T cells, such as enhanced expression of 
survival factors or changes in metabolic state (53, 54), may also 
enhance their resilience. Furthermore, reactivating cells express 
viral proteins at low levels (55, 56), which may limit virus-induced 
disruption of critical host cell functions and reduce the chance of a 
“natural” death. This would also impair viral epitope presentation 
by HLA class I to CTL, impairing immune-mediated clearance. 
Strategies to modulate cellular metabolism (53) or apoptosis (57) 
may hasten cell death due to viral cytopathic effects or immune-
mediated killing. Differences in antigen processing among cell 
types permissive to HIV (58–61) that alter the sequence, kinetics, 
or distribution of epitopes may also have cell-type-dependent 
effects on CTL recognition. Research on antigen processing and 
presentation in reactivating cells to identify optimal CTL epitopes 
should be a priority.
Poor Antiviral cytotoxic t-cell Activity
Cytotoxic T lymphocytes from cART-treated individuals display 
limited ex vivo cytolytic activity against latent CD4+ T cells reacti-
vated using SAHA, although killing can be enhanced by restimu-
lating CTL with viral peptides (7). This indicates that antiviral cells 
are present in blood, but cannot respond effectively – perhaps due 
to lack of perforin or granzyme expression (62, 63). Such non-
reactivity may result from prolonged absence of antigen due to 
cART, triggering establishment of resting central memory T cells 
that display lower cytolytic potential, particularly in lymphoid 
tissues where latent HIV is likely to reside (64). Limited T-cell 
trafficking and/or cytolytic function in lymph nodes may also be 
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a concern in chronic HIV-infected individuals on cART (65, 66). 
Moreover, CTL exhaustion, characteristic of chronic infection 
and manifested by induction of “immune checkpoint inhibitors” 
PD-1, CTLA-4, and other inhibitory receptors (67, 68), may play 
a role. In any case, short-term expansion may select or amplify 
CTL with greater reactivity. Notably, elite controllers demonstrate 
better ability to eliminate latent HIV-infected cells ex vivo (7). 
This is consistent with maintenance of effector memory CTL by 
controllers (69) and suggests that such cells may be necessary to 
immediately recognize reactivating targets. Antibodies that block 
PD-1 (i.e., nivolumab) or CTLA-4 (i.e., ipilimumab) improve 
in  vivo CTL responses against tumor-derived antigens (70), 
and similar approaches are being tested for HIV (71). Although 
studies of chronic SIV-infected rhesus macaques indicated that 
PD-1 blockade enhanced antiviral immunity and reduced plasma 
viremia (72, 73), additional human trials will be critical to evalu-
ate this strategy (74).
Unintended negative consequences of LRAs may also hinder 
reservoir elimination. Immunomodulatory effects of HDACis 
on antigen presentation and immune cell signaling have been 
reported (75, 76). Moreover, treatment with HDACis (romidep-
sin and panobinostat) at clinically relevant doses impaired CTL 
cytokine production and cytolytic responses toward HIV target 
cells (77). The effects of other LRAs on immune function have not 
been reported and should be assessed during pre-clinical testing.
viral evasion from t-cell immunity
Cytotoxic T lymphocyte killing requires recognition of peptides 
presented in complex with HLA class I on the infected cell sur-
face. As such, the ability of HIV to evade CTL through mutational 
escape (78) and Nef-mediated downregulation of HLA class I 
(79) are highly relevant to reservoir elimination efforts.
HIV eludes CTL by altering the sequence of viral epitopes 
in a manner that is predictable based on the HLA class I alleles 
expressed by the host (80, 81). As immune escape (82–86) and 
seeding of the reservoir (87) begin in early infection, the presence 
of escaped epitopes in latently infected cells is a major barrier. 
Indeed, mutations in proviral sequences from cART-treated 
individuals reduced CTL recognition of these cells following 
reactivation (88, 89). Ongoing reservoir seeding poses additional 
challenges. While plasma HIV RNA sequences reflect contempo-
rary viral forms that have survived multiple within-host immune 
bottlenecks, the reservoir is likely to comprise a genetically het-
erogeneous population reflecting multiple descendant lineages 
from the transmitted/founder viral strain, including extinct ones. 
Thus, the latent pool is likely to include escaped and non-escaped 
(archival) forms of the same epitope [though it has been noted 
that the majority of reservoirs carry some escape mutations (88)]. 
Eliminating such a heterogeneous target may require revitaliza-
tion of CTL against non-escaped epitopes as well as elicitation 
or expansion of CTL capable of responding to more diverse 
sequences including escape mutations (11) and subdominant 
epitopes (90). These considerations are somewhat distinct from 
vaccine strategies that traditionally focus on conserved viral 
elements (42, 43). Importantly, in addition to improving clini-
cal outcomes (91–93) and limiting transmission (94, 95), early 
cART reduces reservoir size and diversity (96–99), underscoring 
“seek, test, and treat” approaches to improve the odds of cure. 
Addressing reservoir diversity will nevertheless be important, as 
most individuals initiate cART after reservoirs encoding escape 
mutations are established.
Downregulation of HLA-A and HLA-B molecules by HIV-1 
Nef represents another key CTL evasion strategy (100, 101). While 
no studies have explicitly examined the impact of Nef-mediated 
HLA-downregulation in the context of latency reversal, early 
expression of Nef (before Gag, Pol, and Env) (79) will presumably 
allow it to function similarly in reactivating cells. As such, iden-
tifying early viral epitopes presented before Nef acts (102, 103) 
may be useful for eradication. In contrast to untreated infection, 
where Gag epitopes from incoming virions can be presented to 
CTL prior to Nef-mediated HLA downregulation (104), the earli-
est viral peptides presented following reactivation will be derived 
from accessory/regulatory proteins (Tat, Rev, Nef) expressed 
by the integrated provirus. CTL targeting these proteins are not 
generally associated with control in untreated HIV infection 
(105), but may nevertheless be beneficial (106), particularly for 
Tat (107). Other Nef features may also be relevant. As HLA-B 
alleles display some resistance to Nef-mediated downregulation 
compared to A alleles (108), HLA-B-restricted CTL may be better 
able to recognize reactivating cells [though one study reported 
no difference when cells were restimulated ex vivo with a small 
number of A- versus B-restricted peptides (88)]. HLA-C is not 
downregulated by Nef (109, 110) and HLA-C expression cor-
relates with HIV control (111); thus C-restricted epitopes may be 
attractive targets. In addition, Nef ’s ability to downregulate CD4 
may contribute to reservoir evasion from antibody-dependent 
cellular cytotoxicity (13, 112–114). Notably, patient-derived 
Nef sequences differ in their ability to downregulate HLA class 
I and CD4 (115, 116), and these Nef functions can be attenuated 
through within-host viral adaptation to CTL (117), indicating 
that Nef ’s ability to modulate HIV latency may differ based on 
viral and immunogenetic factors unique to each host. Small 
molecule inhibitors of Nef (118) might enhance the visibility of 
cells following reactivation.
targeting reservoir Diversity
Substantial interindividual heterogeneity in reservoir size and 
sequence (i.e., early versus late cART, prevalence of escape muta-
tions) and host CTL responses (i.e., HLA type, dominant epitopes 
targeted, exhaustion) highlight the complexity of HIV elimina-
tion and imply that a “one-size-fits-all” approach may not be fully 
successful. T-cell-based therapies tailored, in part, to features of 
individual patients may help to move us toward approaches for 
HIV cure.
Genetic characterization of the reservoir
Evaluation of reservoirs focuses mainly on quantifying proviral 
DNA, RNA transcripts, and viral outgrowth (119). Replicative 
competence is also important, although the high levels of gene-
deleted or hypermutated sequences seen in latent reservoirs 
may contribute to inflammation (52). As such, genetic analyses 
of latent HIV sequences as well as host factors (i.e., HLA) (88) 
may pave the way for more personalized immunotherapeutic 
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strategies: next-generation sequencing technologies will be 
particularly useful in this regard. At the most basic level, such 
approaches may identify non-mutated CTL epitopes that can 
serve as immune targets, analogous to use of HIV drug resistance 
genotyping to guide cART (120, 121). Characterization of latent 
HIV diversity may shed light on another key question – that of 
elucidating the chronology of reservoir establishment in different 
cell types and tissues. As CTL escape mutations are highly repro-
ducible in terms of HIV genomic locations (41, 80, 81) and selec-
tion kinetics (84–86, 122, 123), they can provide a crude estimate 
of the relative age of reservoirs. While this has been examined in 
the context of SIV where founder viral sequence and inoculation 
date are known (124, 125), refined estimates of HIV reservoir age 
in humans may require more advanced phylogenetic approaches. 
The problem of dating reservoir sequences within an individual’s 
infection history is similar to that of dating organismal sequences 
of unknown age in the context of macroevolution [i.e., ancient 
DNA (126)] or in the case of HIV, specimens archived from 
historic eras (127, 128). In the latter case, heterochronous HIV 
sequences (i.e., those sampled from different individuals over the 
epidemic’s course) are used to calibrate viral evolutionary rates 
to calendar time using Bayesian (126) or root-to-tip regression 
(127) approaches, allowing the estimation of sampling times 
(tip-ages) for sequences of unknown age. Similarly, within-host 
plasma HIV RNA sequences sampled longitudinally from a 
given individual could be used to calibrate a host-specific HIV 
evolutionary rate that could be used to infer the date of establish-
ment of individual reservoir sequences (129). Such analyses may 
be beneficial to retroactively investigate “partial” successes using 
shock-and-kill (e.g., to investigate whether the age of a reservoir 
predicts its potential for reactivation or CTL elimination).
therapeutic vaccines
Knowing that an epitope is present in the reservoir is only the 
first step. Although no therapeutic vaccine has succeeded in 
suppressing HIV viremia long-term, there is renewed interest to 
couple vaccines with LRAs and cART for additive effects (130). 
HIV persistence in tissues beyond the mucosa and lymphatic 
system, and strategies to enhance CTL patrol of these areas, 
represent major challenges. For example, T follicular helper cells 
located in B-cell follicles of lymph nodes may be a major reservoir 
(131–133); whole-body imaging of SIV-infected rhesus macaques 
revealed ongoing replication in the respiratory tract and lung tis-
sue during cART (134), identifying these as potential sanctuary 
sites. Of note, a Phase II trial examining Tat as a therapeutic vac-
cine target demonstrated restoration of immune cells (including 
effector memory CD8+ T cells) and reduction of proviral DNA 
in blood (107); similar studies to assess other early viral protein 
targets (i.e., Rev and Nef) are also warranted.
Vaccine delivery methods are another consideration. 
Replication-competent and replication-defective viral vectors, 
nucleic acids, proteins, and various adjuvants have been tested 
in the context of HIV vaccines (135). Recently, a replication-
competent simian cytomegalovirus vector expressing T-cell 
antigens has shown promise in a rhesus macaque model (136). 
While this vaccine did not generally prevent SIV infection, 
animals cleared viral RNA and DNA from plasma and tissues 
over the course of 1–2  years without cART (137). Although 
the mechanism of clearance is unknown, the vector’s ability to 
maintain effector memory CTL, including those targeting non-
canonical HLA class II and HLA-E-restricted epitopes, is likely to 
play a role (136, 138). Regardless of the vector used, CTL elicited 
by a vaccine must be cytolytic and capable of trafficking to sites 
where HIV resides.
t-cell-Based therapies
Advances in cancer treatment, including adoptive transfer of 
tumor infiltrating lymphocytes and antigen-specific T-cell recep-
tor (TCR) gene therapy (139), have reinvigorated the field of 
T-cell-based therapies. Cancer and HIV treatment, however, dif-
fer in key respects, risk/benefit considerations being one. Support 
for immunotherapeutic approaches remains strong in the context 
of limited life expectancies and lack of alternative therapies for 
certain cancers, but new HIV treatments must meet a high bar-
rier for implementation due to the potency and safety of cART. 
Nevertheless, the lack of serious adverse events in recent cancer 
immunotherapy trials bodes well for testing such approaches for 
HIV cure (140–142).
Adoptive therapy using autologous virus-specific T cells is not 
new to HIV (143), but studies have thus far been unsuccessful. Over 
the past 20 years, several groups have attempted ex vivo expansion 
and reinfusion of patients’ own CTL (144–148). Limitations of 
these trials, including inefficient engraftment or survival of cells 
and lack of cART, are now addressable using optimized methods 
and improved treatment options. Transfer of autologous tumor 
infiltrating T cells is used routinely for some cancers (149, 150). 
Moreover, successful expansion of HIV-specific CTL from cART-
treated individuals that display ex vivo cytolytic activity against 
autologous reservoir cells (89, 151) indicates that newer adop-
tive T-cell strategies may demonstrate improved HIV efficacy, 
particularly if they can be coupled with LRAs.
Gene therapy approaches represent another possible avenue. 
Modification of CTL to express a heterologous TCR can redirect 
cells toward a specific antigen. Several strategies have been 
employed (140, 149), including native (unmodified) TCRs, 
affinity-enhanced TCRs, and “chimeric” antigen receptors 
(CAR) that typically encode the antigen-binding domain of 
immunoglobulin linked to an intracellular signaling domain 
such as CD3zeta. These methods are being assessed for various 
cancers and they are in earlier stage development for HIV – with 
several reports demonstrating antiviral activity in vitro or in small 
animal models. By reprogramming hematopoietic stem cells to 
express a TCR against the HLA-A*02-restricted Gag SL9 epitope 
(SLYNTVATL), Kitchen et  al. (152) suppressed HIV viremia 
and reduced proviral DNA loads in a humanized mouse model. 
CTL have also been engineered to express HIV-specific CARs, 
including those targeting HIV gp120-expressing cells (153, 154). 
In addition, gene therapy may allow reprogramming of other 
critical CTL functions, including cytotoxicity or lymphoid traf-
ficking potential. Similarly, combining gene therapy approaches 
with other immune modulators (such as blockade of checkpoint 
inhibitors) could provide added benefits. As a note of caution, 
clinical trials using an affinity-enhanced TCR specific for Gag 
SL9 (155) were canceled when severe toxicity was observed for 
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a similar product against melanoma tumor antigen (156). In vivo 
safety thus remains a concern, but these methods offer highly 
flexible strategies to target HIV reservoirs.
conclusion
Extraordinary progress is being made to understand the molecu-
lar mechanisms of HIV latency and to discover viral reactivation 
strategies. Overcoming barriers to eliminate latent cells will be 
critical for shock and kill strategies to succeed, and many impor-
tant issues remain. What viral epitopes are presented efficiently 
by reactivating cells? Is antigen presentation affected by LRAs? 
Does Nef modulate the sensitivity of reactivating cells to CTL 
killing? Can therapeutic vaccines enhance reservoir targeting? 
Will T-cell-based therapeutics be safe and effective? Answers to 
these and other questions will guide future directions in this field 
and may ultimately determine whether we prevail in the quest to 
cure HIV.
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